Moxifloxacin: sequential therapy produces rapid improvements in CAP

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1440, 2004-01, pp. : 11-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin monotherapy on par with combination therapy in CAP

Inpharma, Vol. 1, Iss. 1539, 2006-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Moxifloxacin dominates for CAP

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 539, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Moxifloxacin, nonstandardised antibacterials equivalent in CAP

Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Sequential Intravenous/Oral Moxifloxacin Therapy in Pneumonia: Results of the First Post-Marketing Surveillance Study with Intravenous Moxifloxacin in Hospital Practice

By Barth J.

Clinical Drug Investigation, Vol. 25, Iss. 11, 2005-01 ,pp. : 691-700

Adis International

Access to resources Recommend Favorite

Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

Journal of Digestive Diseases, Vol. 15, Iss. 9, 2014-09 ,pp. : 508-513

John Wiley & Sons Inc

Access to resources Recommend Favorite